• Home
  • About Nanexa
    • Company
    • Management
    • Board
    • Our story
  • Pharmashell®
  • Projects
  • Investors
    • Financial reports
    • Press releases
    • Corporate governance
    • The Stock
    • Analysts
    • Calendar
  • Media
    • Pressreleases
    • Subscribe
    • Publications
    • Presentations
  • Contact
  • English
    • Swedish

Investors

  • Financial reports
  • Pressreleases
  • Corporate governance
    • Shareholders’ meeting
    • Nomination commitee
    • Board
    • Management
    • Auditor
    • Articles of association
  • The Stock
    • Ownership Structure
  • Analysts
  • Calendar

Financial reports

26 August, 2022

Nanexa publishes interim report for January – June 2022

20 April, 2022

Nanexa publishes annual report for 2021

Nanexa publishes interim report for January – March 2022

17 February, 2022

Nanexa publishes year-end report for 2021

10 November, 2021

Nanexa publishes interim report for January – September 2021

20 August, 2021

Nanexa publishes interim report for January – June 2021

6 May, 2021

Interim report Q1 2021

18 February, 2021

Nanexa Year-end report 2020

Investors

  • Financial reports
  • Pressreleases
  • Corporate governance
    • Shareholders’ meeting
    • Nomination commitee
    • Board
    • Management
    • Auditor
    • Articles of association
  • The Stock
    • Ownership Structure
  • Analysts
  • Calendar

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell®. – PharmaShell® is a system that enables next-generation, long-acting injectables with high drug load and manufactured with atomic layer precision. Nanexa develops its own products, and also has partnership agreements with several pharmaceutical companies, including AstraZeneca.

CONTACT

Nanexa AB, Virdings Allé 2, SE-75450 Uppsala, Sweden
Phone: +46 (0) 18 100 300
E-mail: info@nanexa.se
Org nr. 556833-0285

Integritetspolicy
Integritetspolicy för aktieägare

  • English
  • Svenska